How β-estradiol Affects HIV Treatment with Stavudine
Author Information
Author(s): Zhang Mingjie, Huang Qingsheng, Huang Yong, Wood Owen, Yuan Weishi, Chancey Caren, Daniel Sylvester, Rios Maria, Hewlett Indira, Clouse Kathleen A, Dayton Andrew I
Primary Institution: Center for Biologics Evaluation and Research, Food and Drug Administration
Hypothesis
Does the sex steroid hormone β-estradiol affect the replication of HIV-1 or the efficacy of the anti-retroviral drug Stavudine (D4T)?
Conclusion
β-estradiol inhibited both HIV-1 replication in primary human PBL and the antiretroviral efficacy of D4T in PBL cultures.
Supporting Evidence
- β-estradiol resulted in a modest inhibition of HIV-1 replication of ~26%.
- In the presence of 50 nM D4T, 2 nM β-estradiol increased HIV-1 replication from 33% to 74% of control levels.
- The effects were statistically highly significant (p < 0.001).
- No cytotoxicity was observed at the concentrations of drug and hormone tested.
Takeaway
This study found that a hormone called β-estradiol can make it harder for a common HIV medicine, Stavudine, to work properly.
Methodology
Human PBL were infected with HIV-1 in the presence or absence of β-estradiol and D4T, and viral replication was measured after seven days.
Limitations
The study primarily focused on a specific hormone and drug interaction, which may not represent all hormonal effects on HIV treatment.
Participant Demographics
PBL were isolated from HIV sero-negative donors.
Statistical Information
P-Value
0.0009
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website